NCT07267988 Additional Effects Of Brandt-Daroff Exercises With GANS Maneuver On Dizziness And Quality Of Life In Patients With BPPV
| NCT ID | NCT07267988 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Foundation University Islamabad |
| Condition | BPPV |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-09-13 |
| Primary Completion | 2025-12-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-09-13 with a primary completion date of 2025-12-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Benign Paroxysmal Positional Vertigo (BPPV) is the most common cause of recurrent vertigo, with a lifetime prevalence of about 2.4% and a yearly incidence of roughly 0.6%. It results from displaced otoconia within the semicircular canals and is especially common in older adults. BPPV leads to brief, position-provoked episodes of vertigo, dizziness, and imbalance, and reduced quality of life. Although canalith-repositioning maneuvers are highly effective, recurrence is common, emphasizing the need for supportive and adjunctive management strategies.This randomized controlled trial will evaluate the Additional Effects OF Brandt-Daroff Exercise With GANS Maneuver On dizziness And Quality of Life In Patients with BPPV. Thirty patients with BPPV will be recruited at Fauji Foundation Hospital and screened using the Dizziness Handicap Inverntory Scale(DHI) and Vestibular Activities and Participation measure(VAP). Participants will be randomized into two groups: (1) Reciving GANS Manuever Alone (2) GANS Manuever with Brandt-Daroff Exercises(3 sessions per week/40minutes). Dizziness will be assessed using the Dizziness Handicap Inverntory Scale(DHI) , quality of life using the Activities and Participation Measure(VAP) Scale. Outcome measures will be recorded at baseline and post-intervention. Ethical approval will be obtained from FUMC ERC, and data will be analyzed using SPSS v.22.
Eligibility Criteria
Inclusion Criteria: * Diagnosed Patients of Benign Paroxysmal Vertigo (BPPV) * Age between 18-60 * Acute and Chronic BPPV Patients * Positive Dix-Hallpike Test * DHI Scale: Mild-Severe (0-100) Exclusion Criteria: * Patients with a history of vestibular surgery or cochlear * Patients with a history of seizures or epilepsy * Patients with a pacemaker or implantable cardioverter-defibrillator (ICD) * Patients with a history of severe head injury or concussion within the past year * No other vestibular disorders or conditions that may affect balance (e.g., Meniere's disease, labyrinthitis * No musculoskeletal or neurological conditions that may affect balance (e.g., stroke, Parkinson's disease)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07267988 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying BPPV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07267988 currently recruiting?
Yes, NCT07267988 is actively recruiting participants. Contact the research team at rabiaejaz57@gmail.com for enrollment information.
Where is the NCT07267988 trial being conducted?
This trial is being conducted at Islamabad, Pakistan.
Who is sponsoring the NCT07267988 clinical trial?
NCT07267988 is sponsored by Foundation University Islamabad. The trial plans to enroll 30 participants.